The Healthcare Advisory Committee will develop actionable policy solutions, advance accountability for safety and more.
The new federal advisory body, the Healthcare Advisory Committee, will provide advice on modernizing healthcare in the U.S.
FDA-approved Kresladi (marnetegragene autotemcel) is the first gene therapy treating leukocyte adhesion deficiency type I (LADI).
A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.
CMS has launched HealthTech tools to streamline care and digitize the patient experience.
A new CMS Comprehensive Care for Joint Replacement (CJR) Model proposal could lower costs nationwide for Medicare beneficiaries undergoing knee, hip and ankle replacements.
The Statens Serum Institut in Copenhagen found that flu vaccines may protect against heart attack and stroke, even if the flu is still developed after vaccination.
Avlayah (tividenofusp alfa-eknm) has been FDA-approved to treat some individuals with Hunter Syndrome (Mucopolysaccharidosis type II or MPS II).
The novel opioid DFNZ shows potential for pain and opioid use disorder without causing depressed breathing.
Immune-mediated inflammatory disease (IMID) patients have been found to have a high risk of developing cancer, but that risk declines as inflammation decreases.
The U.S. Food and Drug Administration has approved veligrotug-vvze (Lumvoa; Viridian Therapeutics) to treat thyroid eye disease.
The U.S. Food and Drug Administration’s accines and Related Biological Products Advisory Committee voted to recommend approval of the Moderna’s investigational mRNA influenza vaccine, which will be marketed under the brand name mFlusiva, for the prevention of flu in adults age 50 to 64.